400 Optimization of novel pyrido[2,3-b]pyrazine based small molecule fibroblast growth factor receptor 1, 2, 3 & 4 (FGFR) inhibitors into a potential clinical candidate by Angibaud, P, Querolle, O, Berdini, V, Saxty, G, Cleasby, A, Colombel, H, Csoka, I, Esser, N, Gilissen, R, Meerpoel, L, Paulussen, C, Pilatte, I, Poncelet, V, Rees, D.C, Roux, B, Verhulst, T, Tronel, V, Wroblowski, B, Murray, C.W, Vialard, J

Get full text

356 Discovery of novel pyrido[2,3-b]pyrazine as fibroblast growth factor receptor (FGFR-1, 2, 3 & 4) kinase inhibitors with nanomolar affinity by Angibaud, P, Querolle, O, Berdini, V, Saxty, G, Cleasby, A, Colombel, H, Csoka, I, Gilissen, R, King, P, Meerpoel, L, Paulussen, C, Pilatte, I, Poncelet, V, Rees, D.C, Roux, B, Tronel, V, Verhulst, T, Wroblowski, B, Murray, C.W, Vialard, J

Get full text

Crystal structure of calf spleen purine nucleoside phosphorylase complexed to a novel purine analogue by Pereira, H.M., Berdini, V., Cleasby, A., Garratt, R.C.

Get full text

The clinical candidate, ASTX029, is a novel, dual mechanism ERK1/2 inhibitor and has potent activity in MAPK-activated cancer cell lines and in vivo tumor models by Munck, J., Berdini, V., Courtin, A., East, C., Heightman, T., Hindley, C., Kucia-Tran, J., Lyons, J., Martins, V., Muench, S., Murray, C., Norton, D., O’Reilly, M., Reader, M., Rees, D., Rich, S., Thompson, N., Wilsher, N., Woolford, A., Wallis, N.

Get full text

Identification of potent small molecule allosteric inhibitors of SHP2 by Hearn, K., Berdini, V., Chessari, G., Davies, T.G., Day, J.E.H., Hamlett, C., Hiscock, S., Martins, V., Muench, S., Nakatsuru, Y., Ochiiwa, H., Price, A., Rich, S., Shah, A., Shibata, Y., Shimamura, T., Smyth, T., Wallis, N.G., Wilsher, N.E., Johnson, C.N.

Get full text

287 POSTER Fragment-based discovery of AT9283; a multi-targeted kinase inhibitor with potent Aurora kinase activity by Howard, S, Berdini, V, Curry, J, Gill, A.L, Richardson, C.J, Rees, D, Reule, M, Tisi, D, Wyatt, P, Fazal, L

Get full text

Abstract 1361: Fragment based drug discovery of selective inhibitors of Fibroblast Growth Factor Receptor (FGFR) by Saxty, Gordon, Akkari, R, Angibaud, P, Arts, J, Benderitter, P, Berdini, V, Bonnet, P, Cleasby, A, Embrechts, W, Freyne, E, Gilissen, R, King, P, Lacrampe, J, Ligny, Y, Madin, A, Mcclue, S, Mevellec, L, Murray, C W., Newell, H, Page, M, Papanikos, A, Perera, T, Querolle, O, Rees, D C., Rich, S J., Saalau-Bethell, S M., Sement, E, Simmonet, Y, Squires, M, Tronel, V, Ward, G A., Willems, M, B, Wroblowski, Thompson, N T.

Get full text

Abstract 5778: Fragment-based drug discovery of selective inhibitors of fibroblast growth factor receptor (FGFr) by Saxty, Gordon, Squires, M S., Murray, C W., Berdini, V, Ward, G A., Miller, D, Rich, S J., Cleasby, A, Saalau-Bethell, S M., Coyle, J, Madin, A, Carr, M G., O'Brien, M A., Jones, C Griffiths, Vickerstaff, E, Nijjar, R K., Graham, B, Pike, A, Lewis, E J., Perera, T, Angibaud, P, Newell, H

Get full text

Mechanistic Studies of Methylene Chain Propagation in the Fischer–Tropsch Synthesis by Quyoum, Ruhksana, Berdini, Valerio, Turner, Michael L., Long, Helen C., Maitlis, Peter M.

Get full text

332 Fragment-based and structure based optimisation of potent PKB/AKT inhibitors by Wyatt, P., Barford, D., Davies, T., Woodhead, S., Saxty, G., Davis, D., Garrett, M., Raynaud, F., Eccles, S., Berdini, V.

Get full text

117 Identification of novel cyclin dependent kinase 1/2 inhibitors using fragment based high-throughput X-ray crystallography and structure based drug design by Wyatt, P.G., Berdini, V., Carr, M.G., Curry, J.E., Davis, D.J., O'Reilly, M., Saxty, G., Squires, M.S., Woodhead, A.J., Woolford, A.J.-A.

Get full text

Gastrointestinal motility disorder assessment in systemic sclerosis by Savarino, Edoardo, Mei, Federico, Parodi, Andrea, Ghio, Massimo, Furnari, Manuele, Gentile, Adelina, Berdini, Michela, Di Sario, Antonio, Bendia, Emanuele, Bonazzi, Patrizia, Scarpellini, Emidio, Laterza, Lucrezia, Savarino, Vincenzo, Gasbarrini, Antonio

Get full text